Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.

Weiting LiaoJiaxing HuangDavid HuttonGuiqi ZhuQiuji WuFeng WenLiangliang BaiQiu Li

Published in: Liver international : official journal of the International Association for the Study of the Liver (2019)

Cabozantinib at its current cost would not be a cost-effective treatment option for patients with sorafenib-resistant HCC from the payer's perspective in the USA, UK or China. Substantial discounts are necessary to meet conventional cost-effectiveness thresholds.

Keyphrases

metastatic renal cell carcinoma
stem cells
combination therapy
chemotherapy induced